FRC
FRC Logo
CommunityMarkets
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileIDEXX Laboratories, Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
IDXX
IDEXX Laboratories, Inc. Stock AnalysisComprehensive stock analysis for IDEXX Laboratories, Inc. (IDXX) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisIDXX
IDXX
IDEXX Laboratories, Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
IDXX
  1. Home
  2. Stocks
  3. IDEXX Laboratories, Inc.

IDEXX Laboratories, Inc.

🇺🇸IDXX•NASDAQ

IDEXX Laboratories, Inc.

🇺🇸IDXX•NASDAQ
Market cap
$55.20B
Sentiment

Your view on IDXX

Mkt Cap
$55.20B
Sentiment
Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About IDEXX Laboratories, Inc.

Industry
Medical - Diagnostics & Research
Sector
Healthcare
CEO
Jonathan J. Mazelsky
Headquarters
One IDEXX Drive, Westbrook, ME, US
Industry
Medical - Diagnostics & Research
Sector
Healthcare
CEO
Jonathan J. Mazelsky
Headquarters
One IDEXX Drive, Westbrook, ME, US
Description

IDEXX Laboratories, Inc. develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through CAG; Water Quality Products; LPD; and Other segments.

It provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community.

The company also offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; and point-of-care electrolytes and blood gas analyzers and SARS-CoV-2 RT-PCR that are used in the human point-of-care medical diagnostics market; in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers; SNAP rapid assays test kits.

In addition, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; veterinary software and services for independent veterinary clinics and corporate groups.

The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.

Financial Data

Stock Data

Price chart, volume, and trading data.

What moved it

FRC Fair Value Algorithm

What the FRC Fair Value algorithm says it is worth vs. the current price — FRC's own, on every stock.

About this section

Fair value for IDEXX Laboratories, Inc. from FRC's valuation model, read against the market price. IDXX last traded at $700.65, 47.4× trailing earnings — the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for IDEXX Laboratories, Inc.. Starting points for IDEXX Laboratories, Inc.: P/E 47.4, EPS $15.00, beta 1.54 — an Medical - Diagnostics & Research name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

About this section

Dividend history, yield and payout sustainability for IDEXX Laboratories, Inc.. IDEXX Laboratories, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for IDEXX Laboratories, Inc.. Trailing twelve-month EPS for IDEXX Laboratories, Inc. stands at $15.00. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Wall Street Analyst Estimates

Analysts' price targets, ratings, and revenue and EPS estimates.

Third partyAs of Nov 18, 2026 · USD

Price targets, ratings and estimates published by outside analysts. Not FRC research, not a recommendation, and not the FRC Fair Value: that is FRC's proprietary model, built on the cash a company generates.

Current price

—

live quote

Analysts' target

$741.67

average of 6 firms, last 12 months

 

$741.67

Low $700.00

Median $745.00

High $800.00

 

Analyst Ratings

Buy8 firms, last 12 months
  • Strong Buy0
  • Buy5
  • Hold3
  • Sell0
  • Strong Sell0

Earnings Estimate

EPSCurrent QtrDec 2026Next QtrMar 2027Current YearFY Dec 2026Next YearFY Dec 2027
Avg. estimate$3.34$3.91$14.91$16.84
Low estimate$3.30$3.83$14.68$16.62
High estimate$3.38$4.02$14.97$17.03
No. of analysts86910
Year-ago EPS$3.08$3.47$13.08—
Growth+8.4%+12.7%+14.0%—

Revenue Estimate

RevenueCurrent QtrDec 2026Next QtrMar 2027Current YearFY Dec 2026Next YearFY Dec 2027
Avg. estimate$1.18B$1.22B$4.75B$5.16B
Low estimate$1.17B$1.21B$4.72B$5.11B
High estimate$1.19B$1.23B$4.77B$5.21B
No. of analysts851111
Year-ago revenue$1.09B$1.14B$4.30B—
Growth+8.5%+6.8%+10.3%—
Recent analyst actions15 rating and price-target changes, latest Nov 3, 2026 — with the analyst, firm and source

Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep from StreetInsider, Benzinga, Pulse 2.0; as of Nov 18, 2026. Not FRC research or a recommendation.

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for IDEXX Laboratories, Inc.. IDEXX Laboratories, Inc. has reported as a listed company since 1991. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold IDXX16 companies · 8 funds
Compare IDXX with its peers, side by sidePremiumRatios, margins, valuation and leverage of the peers below — one table, one glance.Open Comparable Analysis

Peer companies

Market cap

  • ELANElanco Animal Health IncorporatedDrug Manufacturers - Specialty & Generic$13.2B
  • MRKMerck & Co., Inc.Drug Manufacturers - General$356.1B
  • NEOGNeogen CorporationMedical - Devices$2.4B
  • ZTSZoetis Inc.Drug Manufacturers - Specialty & Generic$34.3B

More Medical - Diagnostics & Research companies

  • MRPSMicrophonics, Inc.OTC
  • MTDMettler-Toledo International Inc.NYSE$34.4B
  • MVF.AXMonash IVF Group LimitedASX
  • MYGNMyriad Genetics, Inc.NASDAQ$534M
  • NDRAENDRA Life Sciences Inc.NASDAQ$7M
  • NEONeoGenomics, Inc.NASDAQ$2.0B
  • NSTMNovelStem International Corp.OTC$653,997
  • NTRANatera, Inc.NASDAQ$41.8B
  • OCLGOncologix Tech, Inc.OTC$73,662
  • OPKOPKO Health, Inc.NASDAQ$1.2B
  • PEB.AXPacific Edge LimitedASX
  • PFGTFPacific Edge LimitedOTC$238M

ETFs holding IDEXX Laboratories, Inc.

% of the fund

  • VOOVanguard S&P 500 ETF$1.0T in assets0.07%
  • VTIVanguard Total Stock Market ETF$689.2B in assets0.06%
  • QQQInvesco QQQ Trust, Series 1$446.1B in assets0.26%
  • VOVanguard Mid-Cap ETF$103.4B in assets0.42%
  • PHOInvesco Water Resources ETF$2.1B in assets8.16%
  • IHIiShares US Medical Devices ETF$4.0B in assets5.47%
  • FIWFirst Trust Water ETF$1.9B in assets4.70%
  • QQEWFirst Trust Nasdaq-100 Select Equal Weight ETF$1.6B in assets2.80%

Largest holders first, then the funds most concentrated in IDXX.

Open Comparable Analysis
Ownership & News

Institutional Ownership

Which funds and firms own the stock.

About this section

Which institutions hold IDEXX Laboratories, Inc., and how their positions are changing. At a $55.20B market value, institutional positions materially move IDEXX Laboratories, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.

Insider Trading

Recent buying and selling by company executives.

About this section

Buying and selling by IDEXX Laboratories, Inc. executives and directors. Shares of IDEXX Laboratories, Inc. have traded between $356.14 and $735.00 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.

Senate Trading

U.S. Senator disclosures filed under the STOCK Act.

About this section

U.S. Senate disclosures naming IDEXX Laboratories, Inc.. IDEXX Laboratories, Inc. is a $55.20B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely.

House Trading

U.S. Representative disclosures filed under the STOCK Act.

About this section

U.S. House of Representatives disclosures naming IDEXX Laboratories, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals.

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for IDEXX Laboratories, Inc.. Coverage tracks IDEXX Laboratories, Inc. within Medical - Diagnostics & Research (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of IDEXX Laboratories, Inc.

IDXX Analysis
Fair
Past1
Growth4
Health3
Profit5
Value1

News

Latest Market News